| scholarly article | Q13442814 |
| P2093 | author name string | Jozélio Freire de Carvalho | |
| Simone Appenzeller | |||
| Sandra Gofinet Pasoto | |||
| P2860 | cites work | Antiphospholipid syndrome | Q55891386 |
| Epileptic seizures in systemic lupus erythematosus | Q57086591 | ||
| Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal | Q69928846 | ||
| Epileptic seizures in cerebral arterial occlusive disease | Q70299294 | ||
| Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons | Q72350707 | ||
| Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus | Q79171865 | ||
| A protocol for determination of anticardiolipin antibodies by ELISA | Q81201365 | ||
| Thrombosis, abortion, cerebral disease, and the lupus anticoagulant | Q24675412 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) | Q28243974 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Features associated with epilepsy in the antiphospholipid syndrome | Q33361525 | ||
| A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II | Q33495339 | ||
| Subclinical hyperthyroidism and dementia: the Sao Paulo Ageing & Health Study (SPAH). | Q33591840 | ||
| Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. | Q34093232 | ||
| Central nervous system involvement in the antiphospholipid (Hughes) syndrome | Q35069507 | ||
| Laboratory diagnosis of the antiphospholipid syndrome | Q35099172 | ||
| New approaches for managing antiphospholipid syndrome | Q37404485 | ||
| Seizure during hyperbaric oxygen therapy for carbon monoxide toxicity: a case series and five-year experience | Q37446351 | ||
| Neurological manifestations of antiphospholipid syndrome | Q37700770 | ||
| Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome | Q37853050 | ||
| Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction | Q40371891 | ||
| Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome | Q41238775 | ||
| Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients | Q41935758 | ||
| Decreased sensitivity to nicotine-induced seizures as a consequence of nicotine pretreatment in long-sleep and short-sleep mice | Q42213613 | ||
| Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation | Q45712961 | ||
| Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes | Q48245672 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| primary antiphospholipid syndrome | Q63878006 | ||
| P304 | page(s) | 981519 | |
| P577 | publication date | 2012-03-25 | |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke | |
| P478 | volume | 2012 |
| Q38885685 | Anti-phospholipid Antibodies and Smoking: An Overview |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q34003460 | Cardiovascular risk factors in the antiphospholipid syndrome |
| Q39601857 | Epilepsy and tobacco smoking: a cross-sectional study |
| Q35185887 | Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus |
| Q38753510 | Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. |
| Q37704593 | Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage |
| Q38179855 | Tobacco smoking, epilepsy, and seizures |
Search more.